NOVEL SOLUBILITY-ENHANCING PROTEIN EXPRESSION TECHNOLOGY

Information

  • Research Project
  • 8501542
  • ApplicationId
    8501542
  • Core Project Number
    R44GM089553
  • Full Project Number
    5R44GM089553-03
  • Serial Number
    089553
  • FOA Number
    PA-11-096
  • Sub Project Id
  • Project Start Date
    8/1/2009 - 16 years ago
  • Project End Date
    6/30/2015 - 10 years ago
  • Program Officer Name
    EDMONDS, CHARLES G.
  • Budget Start Date
    7/1/2013 - 12 years ago
  • Budget End Date
    6/30/2015 - 10 years ago
  • Fiscal Year
    2013
  • Support Year
    03
  • Suffix
  • Award Notice Date
    7/9/2013 - 12 years ago
Organizations

NOVEL SOLUBILITY-ENHANCING PROTEIN EXPRESSION TECHNOLOGY

DESCRIPTION (provided by applicant): A major goal in the post-genomic era is to express the vast collection of protein- coding sequences, eventually resulting in a better understanding of protein interactions and the development of novel therapeutics. The most favored host for heterologous recombinant protein expression is Escherichia coli. Despite many improvements, producing soluble proteins in E. coli is still a major bottleneck for structural genomics: typically, >50% of recombinant proteins are expressed in an insoluble form. Methods to optimize soluble protein expression are labor- and reagent-intensive. They involve screening for growth conditions, host strains, and solubility enhancing fusion partners and assessing solubility by cell lysis, fractionation and gel electrophoresis. The goal of the proposed research is to develop an integrated system of expression vectors and host strains to improve soluble expression of recombinant proteins. The system will include a novel yellow fluorescent protein tag that will function as an in vivo reporter of expression and solubility of the recombinant protein. This simple visual readout will facilitate individual and high-throughput expression screening. Further, we will exploit this reporter system to conduct genetic screens for novel protein fusion partners that promote soluble expression of difficult targets. We will validate the resulting solubility tags and incorporate them into a suite of products for protein expression and purification. The resulting system will enable high-throughput optimization of soluble protein expression through parallel screening of fusion partners, host strains, and expression conditions. It will likewise be a great advantage for expression of individual proteins, minimizing the use of labor and reagents. The success of these efforts is expected to have a major impact on biomedicine, both for academic purposes and for development of protein therapeutics.

IC Name
NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
  • Activity
    R44
  • Administering IC
    GM
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    649620
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    859
  • Ed Inst. Type
  • Funding ICs
    NIGMS:649620\
  • Funding Mechanism
    SBIR-STTR RPGs
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    LUCIGEN CORPORATION
  • Organization Department
  • Organization DUNS
    019710669
  • Organization City
    MIDDLETON
  • Organization State
    WI
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    535621614
  • Organization District
    UNITED STATES